Le Lézard
Classified in: Health, Covid-19 virus
Subject: AVO

Citizens for Radioactive Radon Reduction launches a new awareness campaign: "DO THE ASK ... Talk to your doctor about radon"


WATERLOO, Ill., Jan. 21, 2022 /PRNewswire-PRWeb/ -- "The urgency we feel to address long-standing radon and environmental issues as a medical connector has only increased due to COVID-19 and climate change," said Gloria Linnertz, President. "Across the public and private sectors, it is clear that we must do more ? to take action, help others convene, and serve as a catalyst for a broad-based, collective response to the critical issues affecting our homes, schools, and workplaces when it comes to radon gas."

CR3 also announced immediate commitment and related collaborative actions in support of increased advocacy, dialogue, and engagement with other organizations to further efforts to reduce radon gas and its lung cancer effects.

"It is well known through years of studies, that radon gas kills approximately 21,000 people per year, as stated by the U.S. Surgeon General. It is well known that it is the second leading cause of lung cancer and number one among never-smokers," said Jacquelyn Nixon, CR3 Director of Marketing and Cancer Survivor, "so why are we not looking at people in high radon risk areas, encouraging healthcare professionals to discuss the risks and encouraging patients to test their homes? Additionally, the outcomes should be added to their patient history. This could only improve diagnosis. Approximately 75% of the lung cancer patients who find out about radon are in stage III or stage IV."

Suggested actions taken to help start a dialogue between patients and their doctors could include:

Additional focus on awareness regarding other radiation exposures and individual lung risk factors, that increase the difficulty of responding to those with concerns include:

Expanding perspectives is a critical aspect of how Citizens for Radioactive Radon Reduction drives its radon advocacy. Over the last decade, the organization has hosted conversations, projects, and publications for communities to cultivate radon and lung cancer awareness. It's now time to build bridges and encourage the medical community to take a strong look at radon and how it is affecting the lungs.

DO THE ASK: https://joom.ag/FKHI/p12
#LungsWorkFromHome     #f(eD)>>f(C,R,M)
"The function of Early Detection is Greater than the function of Chemo, Radiation or Medication"
CR3 News Magazine 2022 VOL 1: January "National Radon Action Month"     Direct Link: https://joom.ag/FKHI
CR3 News Magazine Newsstand: https://newsstand.joomag.com/en?q=CR3+News+Magazine
Facebook: https://www.facebook.com/citizens4radonreduction.org
[email protected]

Media Contact

Gloria J. Linnertz, President, Citizens for Radioactive Radon Reduction, (618) 830-4660, [email protected]

Jacquelyn E. Nixon, Dir. Mktg & Communications, Citizens for Radioactive Radon Reduction, 412-961-1980, [email protected]

Twitter

 

SOURCE Citizens for Radioactive Radon Reduction


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: